Cite
HARVARD Citation
Qin, Y. et al. (2017). Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. Leukemia & lymphoma. 58 (6), pp. 1384-1393. [Online].